392 related articles for article (PubMed ID: 24952358)
21. Analysis of multipotent mesenchymal stromal cells used for acute graft-versus-host disease prophylaxis.
Kuzmina LA; Petinati NA; Shipounova IN; Sats NV; Bigildeev AE; Zezina EA; Popova MD; Drize NJ; Parovichnikova EN; Savchenko VG
Eur J Haematol; 2016 Apr; 96(4):425-34. PubMed ID: 26115424
[TBL] [Abstract][Full Text] [Related]
22. Safety and Efficacy of Infliximab Therapy in the Setting of Steroid-Refractory Acute Graft-versus-Host Disease.
Yalniz FF; Hefazi M; McCullough K; Litzow MR; Hogan WJ; Wolf R; Alkhateeb H; Kansagra A; Damlaj M; Patnaik MM
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1478-1484. PubMed ID: 28495641
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Acute Graft-versus-Host Disease in Childhood with Extracorporeal Photochemotherapy/Photopheresis: The Padova Experience.
Calore E; Marson P; Pillon M; Tumino M; Tison T; Mainardi C; De Silvestro G; Rossin S; Franceschetto G; Carraro E; Pescarin M; Varotto S; Destro R; Gazzola MV; Basso G; Messina C
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1963-72. PubMed ID: 26183078
[TBL] [Abstract][Full Text] [Related]
24. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.
Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM
Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245
[TBL] [Abstract][Full Text] [Related]
25. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
[TBL] [Abstract][Full Text] [Related]
27. Safety of autologous freshly expanded mesenchymal stromal cells for the treatment of graft-versus-host disease.
Stenger E; Giver CR; Langston A; Kota D; Das PK; Chinnadurai R; Galipeau J; Waller EK; Qayed M
Front Immunol; 2022; 13():959658. PubMed ID: 36189324
[TBL] [Abstract][Full Text] [Related]
28. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study.
Muroi K; Miyamura K; Ohashi K; Murata M; Eto T; Kobayashi N; Taniguchi S; Imamura M; Ando K; Kato S; Mori T; Teshima T; Mori M; Ozawa K
Int J Hematol; 2013 Aug; 98(2):206-13. PubMed ID: 23860964
[TBL] [Abstract][Full Text] [Related]
29. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
[TBL] [Abstract][Full Text] [Related]
31. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy.
von Bahr L; Sundberg B; Lönnies L; Sander B; Karbach H; Hägglund H; Ljungman P; Gustafsson B; Karlsson H; Le Blanc K; Ringdén O
Biol Blood Marrow Transplant; 2012 Apr; 18(4):557-64. PubMed ID: 21820393
[TBL] [Abstract][Full Text] [Related]
32. A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease.
Soder RP; Dawn B; Weiss ML; Dunavin N; Weir S; Mitchell J; Li M; Shune L; Singh AK; Ganguly S; Morrison M; Abdelhakim H; Godwin AK; Abhyankar S; McGuirk J
Stem Cell Rev Rep; 2020 Oct; 16(5):979-991. PubMed ID: 32740891
[TBL] [Abstract][Full Text] [Related]
33. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
34. Remestemcel-L for the treatment of graft versus host disease.
Locatelli F; Algeri M; Trevisan V; Bertaina A
Expert Rev Clin Immunol; 2017 Jan; 13(1):43-56. PubMed ID: 27399600
[TBL] [Abstract][Full Text] [Related]
35. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
Ringdén O; Uzunel M; Rasmusson I; Remberger M; Sundberg B; Lönnies H; Marschall HU; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
Transplantation; 2006 May; 81(10):1390-7. PubMed ID: 16732175
[TBL] [Abstract][Full Text] [Related]
36. To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors.
Parody R; Caballero D; Márquez-Malaver FJ; Vázquez L; Saldaña R; Madrigal MD; Calderón C; Carrillo E; Lopez-Corral L; Espigado I; Carmona M; López-Villar O; Pérez-Simón JA
Eur J Haematol; 2013 Nov; 91(5):448-55. PubMed ID: 23710624
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of human umbilical cord derived mesenchymal stem cell therapy in children with severe aplastic anemia following allogeneic hematopoietic stem cell transplantation: a retrospective case series of 37 patients.
Si Y; Yang K; Qin M; Zhang C; Du Z; Zhang X; Liu Y; Yue Y; Feng Z
Pediatr Hematol Oncol; 2014 Feb; 31(1):39-49. PubMed ID: 24383400
[TBL] [Abstract][Full Text] [Related]
38. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
39. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
40. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
